Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · IEX Real-Time Price · USD
4.300
-0.150 (-3.37%)
At close: Apr 25, 2024, 4:00 PM
4.330
+0.030 (0.70%)
After-hours: Apr 25, 2024, 7:41 PM EDT
Pyxis Oncology Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Pyxis Oncology stock have an average target of 9.80, with a low estimate of 7.00 and a high estimate of 15. The average target predicts an increase of 127.91% from the current stock price of 4.30.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Pyxis Oncology stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 2 | 2 | 3 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +62.79% | Apr 10, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $7 | Buy | Reiterates | $7 | +62.79% | Mar 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $4 → $7 | Strong Buy | Maintains | $4 → $7 | +62.79% | Mar 22, 2024 |
| BTIG | BTIG | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +86.05% | Feb 9, 2024 |
| Leerink Partners | Leerink Partners | Buy Initiates $12 | Buy | Initiates | $12 | +179.07% | Jan 23, 2024 |
Financial Forecast
Revenue This Year
4.59M
Revenue Next Year
510.00K
from 4.59M
Decreased by -88.89%
EPS This Year
-0.93
from -1.85
EPS Next Year
-1.22
from -0.93
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 8.4M | 2.1M | 26.3M | 27.3M | 66.5M |
| Avg | 4.6M | 510,000 | 9.2M | 9.5M | 38.9M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | -54.2% | 5,047.1% | 197.4% | 598.9% |
| Avg | - | -88.9% | 1,700.0% | 3.7% | 308.5% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.28 | -0.99 | -1.00 | -1.12 | -1.01 |
| Avg | -0.93 | -1.22 | -1.27 | -1.45 | -1.61 |
| Low | -1.17 | -1.42 | -1.43 | -2.01 | -2.64 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.